Ann Arbor Stage IV Marginal Zone Lymphoma
5 clinical trials · Condition
◉ Watch Ann Arbor Stage IV Marginal Zone Lymphoma
| Record | Firm | Date |
|---|---|---|
| ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma (NCT05025800) | M.D. Anderson Cancer Center | 2021-10-13 |
| Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma (NCT04323956) | Mayo Clinic | 2020-06-15 |
| Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma (NCT02532257) | M.D. Anderson Cancer Center | 2016-04-11 |
| Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma (NCT00695786) | M.D. Anderson Cancer Center | 2008-06-10 |
Track Ann Arbor Stage IV Marginal Zone Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.